AstraZeneca dips on US drug approval delay, as FTSE falters

AstraZeneca shares have slipped back after news of a delay to the possible US approval of one of its most important drugs. The US Food and Drug Administration said it would complete its review of heart drug Brilinta – originally due tomorrow – three months later than expected on December 16. It said it needed more time to study the application, and the news sent Astra’s shares 37p lower to £33 …

Leave a comment